Portal del Investigador
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Abstract
Background Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial.
Más información
| Título según WOS: | Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| Título de la Revista: | LANCET NEUROLOGY |
| Volumen: | 19 |
| Número: | 7 |
| Editorial: | Elsevier Science Inc. |
| Fecha de publicación: | 2020 |
| Página de inicio: | 582 |
| Página final: | 590 |
| DOI: |
10.1016/S1474-4422(20)30173-3 |
| Notas: | ISI |